Novome raises $33M series A, shoots for the gut with engineered microbes

Novome’s engineered microbe platform attracted DCVC Bio to lead its $33 million series A because of the potential it offers for a non-invasive mechanism to deliver biologics to the gut, a long-standing industry goal. The funds will provide enough runway for

Read the full 415 word article

User Sign In